All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Although the prognosis of patients with core-binding factor acute myeloid leukemia (CBF-AML) is favorable, there is still a need for an improvement in the long-term survival for patients. KIT is highly expressed in patients with CBF-AML, and is associated with poor outcomes.1 Dasatinib, a multi-kinase inhibitor, with KIT inhibitory activities, in combination with cytarabine have been shown to significantly prolong the survival of KIT mutated mice compared to dasatinib alone.2 Hence the rationale for the study by a group of researchers from the German-Austrian AML study group.
The AMLSG group conducted an open-label phase Ib/IIa AMLSG 11–08 trial (NCT00850382), which is investigating the safety, feasibility, and efficacy of the addition of dasatinib to intensive induction and consolidation chemotherapy and administered as a single agent for one-year maintenance in first line treatment for adult patients with newly diagnosed CBF-AML. The primary efficacy objective of this study was to assess feasibility of dasatinib given after intensive induction and consolidation therapy and as single-agent maintenance for one year. The results of the study were reported in Leukemia.1
Eighty-nine patients (median age = 49.5 years, range, 19–75) with newly diagnosed CBF-AML started treatment in this study at 49 AMLSG sites in Germany (n = 44) and Austria (n = 5). Of these 89 patients, t(8,21) and inv(16) were detected in 37 and 52 patients respectively. The primary combined end point of the study was the rate of early (ED) and hypoplastic (HD) deaths, rate of pleural or pericardial effusion (PEF) 3°/4°, rate of liver toxicity (LTOX) 3°/4° not improving to 2° or less within 14 days after discontinuing responsible medication, and the rate of refractory disease (RD).
The AMLSG group concluded that the addition of dasatinib to intensive chemotherapy and administration as single-agent maintenance therapy in CBF-AML was “tolerable and feasible”. They further added that the “beneficial safety profile” in the AMLSG 11–08 trial together with the promising indications for response and long-term outcome provided the basis to begin a phase III randomized study (NCT02013648) assessing dasatinib in combination with intensive treatment and for maintenance in adult patients with newly diagnosed CBF-AML.
Subscribe to get the best content related to AML delivered to your inbox